Nature Medicine, Published online: 21 February 2025; doi:10.1038/d41591-025-00014-y
The phase 3 CheckMate 8HW trial shows superior outcomes with nivolumab plus ipilimumab (compared with nivolumab monotherapy) in patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer.
